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It is well established that lactate can be used as an energy substrate by the brain by conversion
to pyruvate and a subsequent oxidation in the mitochondria. Knowing the need for readily
metabolizable substrates directly after ischemia and the protective effect of lactate after
excitotoxicity, the aim of this study was to investigate whether lactate administration directly after
ischemia could be neuroprotective. In vitro, the addition of 4mmol/L L-lactate to the medium of rat
organotypic hippocampal slices, directly after oxygen and glucose deprivation (OGD), protected
against neuronal death, whereas a higher dose of 20mmol/L was toxic. In vivo, after middle cerebral
artery occlusion in the mouse, an intracerebroventricular injection of 2lL of 100mmol/L L-lactate,
immediately after reperfusion, led to a significant decrease in lesion size, which was more
pronounced in the striatum, and an improvement in neurologic outcome. A later injection 1h after
reperfusion did not reduce lesion size, but significantly improved neurologic outcome, which is an
important point in the context of a potential clinical application. Therefore, a moderate increase in
lactate after ischemia may be a therapeutic tool.
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Introduction
Stroke is the first cause of disability and the third
cause of death in the world (Feigin et al, 2003;
Murray and Lopez, 1997). Approximately 80% of
strokes are ischemic and most of the infarcts involve
the territory of the middle cerebral artery. During an
ischemic stroke, glucose and oxygen supply to the
brain decreases, leading to a cascade of damaging
mechanisms. Disruption of brain metabolism is
clearly a key element in stroke; a better knowledge
of its cellular and molecular determinants may lead
to novel therapeutic targets.
Glucose was believed to be the only energy
substrate for neurons until Schurr et al showed 20
years ago that lactate, as a sole energy substrate, can
support normal synaptic function in rat hippocampal
slices (Schurr, 2006; Schurr et al, 1988), opening the
possibility that lactate produced during ischemia
might not just be an end product, but might also be
used as a substrate for energy metabolism. A few
years later, Pellerin and Magistretti (1994) proposed
their astrocyte–neuron lactate shuttle hypothesis, in
line with the idea that lactate can be used by
neurons.
On the basis of this hypothesis, several studies
have tested whether lactate is beneficial to neurons
under pathologic conditions, such as ischemia,
glutamate excitotoxicity, and traumatic brain injury,
and showed promising results even if the use of
lactate as an energy substrate by neurons is still a
source of controversy (Hertz, 2008). In vitro, on
hippocampal slices, it has been shown that lactate,
either endogenously produced during hypoxia or
applied exogenously, can be used after hypoxia, is
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preferential to glucose during the reoxygenation
period (Cater et al, 2003; Schurr et al, 1997b), and
is protective against glutamate excitotoxicity (Schurr
et al, 1999). In vivo, lactate administered to cortical
superfusate during and after global ischemia in rat,
allows a better recovery of the electrocorticogram
during reperfusion and reduces amino-acid release
(Phillis et al, 1999). When perfused in combination
with glutamate, lactate has been shown to protect
against glutamate excitotoxicity and to reduce lesion
size (Ros et al, 2001). Another study using an
inhibitor of lactate transport, which also inhibits
the entry of pyruvate into the mitochondria, showed
an important neuroprotective effect of endogenously
produced lactate during global ischemia (Schurr
et al, 2001). Furthermore, lactate administration in
patients after traumatic brain injury improved
neurologic outcome (Ichai et al, 2009).
There is growing evidence showing that lactate is
required to sustain neuronal recovery directly after
ischemia. However, the effect of lactate administra-
tion after reperfusion has never been tested. There-
fore, the aim of this study was to test a potential
neuroprotective effect of lactate administration at the
end of ischemia or later.
Materials and methods
All animal experiments were conducted in accordance
with the guidelines of the cantonal veterinary office.
Organotypic Hippocampal Slice Cultures
Hippocampal slice cultures obtained from P12 rats were
subjected to in vitro ischemia by exposure to reduced
oxygen and glucose concentrations (oxygen and glucose
deprivation, OGD), as described previously (Hirt et al,
2004). Briefly, 350-mm-thick coronal hippocampal slices
were cultured on porous membranes (Millicell; Millipore,
Billerica, MA, USA) in a medium containing 25% horse
serum (Oxoid, Hampshire, UK), 50% minimal essential
medium supplemented with HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) and sodium bicarbonate
(MEM; Gibco, Paisley, UK), 25% HBSS (Hanks’ balanced
salt solution; Gibco), 2mmol/L L-glutamine and 6.4mg/mL
D-glucose. Cultures were grown at 331C, 100% humidity,
and 5% CO2 for 3 days. The medium was replaced by a
fresh identical medium at day 3, and then by a medium
with 15% horse serum, 60% MEM, 25% HBSS, and
2mmol/L L-glutamine at day 6. For OGD, slices were
transferred to a serum-free hypoglycemic medium, DMEM
(Dulbecco’s modified Eagle’s medium; D5030; Sigma,
St Louis, MO, USA), supplemented with 1mmol/L
D-glucose and 2mmol/L L-glutamine, in a humidified
hypoxia chamber (COY, Grass Lake, MI, USA) with a
hypoxic atmosphere of 5% O2, 5% CO2, and 90% N2 at
371C for 30mins. Sodium L-lactate (Fluka, Sigma-Aldrich,
Buchs, Switzerland) diluted in 1phosphate-buffered
saline (PBS) (stock solution of 500mmol/L) was adminis-
tered immediately after OGD (final concentration of 1, 4,
10, or 20mmol/L). Cell death was determined in the
neuronal CA1 region after incubation in 5mg/mL propi-
dium iodide (Sigma) for 30mins. Propidium iodide
fluorescence emission (excitation wavelength 568nm)
was measured 48h after OGD. After subtracting back-
ground fluorescence, the results were expressed as a
percentage of maximal cell death obtained by incubating
the hippocampal slice cultures in 1 PBS for 24h at 41C.
Cell death was averaged for the four slices of each culture.
Transient Middle Cerebral Artery Occlusion in the
Mouse
A total of 13 male ICR-CD1 mice (weighing 24 to 34 g,
Charles River, L’Arbresle, France) were anesthetized by
an intraperitoneal injection of 8mg/kg xylazine (Rompun
2%, Bayer, Zu¨rich, Switzerland) + 100mg/kg ketamine
(Ketanarkon 100, Streuli Pharma AG). A second dose of
4mg/kg xylazine+ 50mg/kg ketamine was added after
40mins of anesthesia. A total of 26 male ICR-CD1
mice (22 to 32 g, Charles River) were anesthetized and
maintained under 1.5% to 2% isoflurane in 30% oxygen
and 70% nitrous oxide using a face mask. At 0 h, ischemia
was induced by inserting an 11-mm silicone-coated 8-0
filament through the left common carotid artery into the
internal carotid artery (see Wiegler et al (2008) and
references therein). The filament was withdrawn after 30
(for the mice anesthetized with xylazine–ketamine) or
60mins (for the mice anesthetized with isoflurane),
allowing reperfusion. Regional cerebral blood flow was
measured by LDF (laser-Doppler flowmetry) (Periflux 5000,
Perimed, Stockholm, Sweden) with a flexible probe fixed
on the skull, 1mm posteriorly and 6mm laterally from the
bregma. Throughout the entire operation, regional cerebral
blood flow was monitored and maintained under 20% of
the baseline level during ischemia and above 50% of the
baseline level after reperfusion. Throughout surgery and
until awaking, rectal temperature was maintained
at 37±0.51C using a temperature control unit (FHC,
Bowdoinham, ME, USA).
Mice were administered 0.025mg/kg of buprenorphine
subcutaneously for analgesia at the end of the operation.
Once the animals were awake, they were housed in an
incubator at 311C. The mice were killed 48h after ischemia.
To mimic the in vitro condition, we estimated that the
intracerebroventricular injection of 2mL of 100mmol/L
L-lactate would increase the cerebrospinal fluid lactate
concentration in vivo by B4mmol/L in a mouse. L-lactate
was diluted to a final concentration of 100mmol/L in
1 PBS (pH 7.4). Randomly, 2 mL of either the 100mmol/L
L-lactate solution or vehicle (1 PBS, pH 7.4) was injected
intracerebroventricularly (intracerebroventricular, 0.9mm
laterally, 0.1mm posteriorly, 3.1mm deep from the bregma)
using a Hamilton syringe (Hamilton Company, Bonaduz,
Switzerland) (Hirt et al, 2004) on the left side directly
after reperfusion (at 35 or 70mins from the beginning of
ischemia) or at 120mins from the beginning of ischemia.
For this later injection (120mins), animals were reanesthe-
tized using an intraperitoneal injection of 4mg/kg
xylazine + 50mg/kg ketamine. For the first group of mice,
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anesthetized with xylazine–ketamine, the experimentator
was not blinded to the treatment group at injection time,
but lesion size measurements were blinded. For all the
mice anesthetized with isoflurane, the experiment was
blinded from the beginning of the first operation until the
end of data analysis.
Determination of Ischemic Lesion Volumes
Animals were killed at 48h after the onset of focal ischemia
and 20-mm-thick, 720-mm-apart, coronal cryostat sections
were stained with cresyl violet for histologic determination
of lesion size. A digitalized image of the Nissl-stained
tissue was obtained under a light stereomicroscope (Leica
MZ16FA, Leica, Heerbrugg, Switzerland). The lesion area
was determined by an examiner blinded for the treatment
group using ImageJ software (NIH, Bethesda, MD, USA,
http://rsb.info.nih.gov/ij/) on stained sections. Direct
infarct volume was calculated by multiplying the sum
of the infarct areas on each section by the spacing
distance. To avoid bias due to edema, an indirect lesion
size was calculated as follows: indirect lesion=
Volumecontralateral(Volumeipsilateraldirect infarct volume)
(Swanson et al, 1990).
Neurologic Deficits
A neuroscore composed of three tests was assessed
48h after ischemia for mice operated under isoflurane
anesthesia. In this neuroscore, each test has a maximum of
three points. The first test evaluates the neurologic deficit
and is graded for severity, as described previously (Hirt
et al, 2004) (0: no observable neurologic deficit; 1: failure to
extend the right forepaw; 2: circling to the contralateral
side, and 3: loss of walking or righting reflex). The second
test is a beam walking test (Carter et al, 2001) (0: mice walk
directly to the end of the beam; 1: mice can walk along the
beam, but slip a few times; 2: mice cannot walk more than
a few steps. 3: mice do not move). The third test is the
Rotarod treadmill (UgoBasile, Comerio, Italy) (Carter et al,
2001) test. The mice were placed on the rotating drum, set
to accelerate uniformly from 4 to 40 r.p.m., and their
latency to fall from the drum was recorded. The animals
were trained on 2 different days before surgery, with two
trials in each training session. The test was then performed
2 days after middle cerebral artery occlusion (MCAO), with
two consecutive trials for each animal. The better of the
two trials was selected. Points were attributed on the basis
of performances expressed as a percentage of the best
performance before ischemia (0:90% to 100% and then 0.5
point for each 15% decrease).
In VivoMagnetic Resonance Studies of Lactate-Injected
Mice
To evaluate the distribution of the intracerebroventri-
cularly injected lactate, six ICR-CD1 mice (weighing 29 to
33 g) were measured by magnetic resonance (MR) imaging
and spectroscopy before and after an intracerebroventri-
cular injection of 2mL of 100mmol/L L-lactate. Four
additional ICR-CD1 mice (29 to 35 g) were measured after
an intracerebroventricular injection of 2 mL of PBS to
eliminate any possible lactate contribution due to the
intracerebroventricular injection itself.
All MR studies were carried out in a horizontal, 14.1-T/
26-cm magnet (Magnex Scientific, Abingdon, UK), as
described previously (Lei et al, 2009).
Throughout the entire MR studies, including the
intracerebroventricular injection, the animals were main-
tained in an anesthetized state with 1% to 2% isoflurane
mixed with O2 and stereotaxically fixed with two ear
pieces and a bite piece in a holder (RAPID Biomedical
GmbH, Rimpar, Gemany). During the mean time, the
animal was simultaneously monitored for breathing and
temperature using an MR-compatible monitor system
(Model 1025, SA Instruments, Stony Brook, NY, USA),
and rectal temperature was maintained at B37.01C by
circulating warm water.
Briefly, multislice T2-weighted images were acquired
using the fast spin-echo technique (Hennig, 1988),
with TEeff (effective echo time) = 50msecs and TR
(repetition time) 6,000msecs to locate the volume of
interest in the left striatum (6 to 8 mL) or cortex (2.2 to
2.5 mL). Thereafter, all first- and second-order shim terms
over the volume of interest were altered accordingly, using
the echo-planar version of FASTMAP (see Mlynarik et al
(2006) and references therein), which resulted in a water
line width within 25Hz. Localized 1H-MR spectrum was
obtained using the SPECIAL techniques, TE/TR=2.8/
4,000msec in combination with outer volume suppression
and VAPOR water suppression (see Mlynarik et al (2006)
and references therein). To sustain sufficient signal-to-
noise ratios from such microliter volumes, 240 and 480 of
such spectra were acquired for the striatum and cortex,
respectively.
The in vivo 1H-MR spectra obtained from each study
were processed as in Tkac et al, (2007), frequency drift was
corrected, summed and eddy current was compensated
using the water signal from the same volume of interest.
Thereafter, absolute quantification was obtained using a
linear combination analysis method, LCModel, assuming
80% tissue water content (see Tkac et al (2007) and
references therein).
Statistics
All data are presented as mean±s.d. Statistical analyses
were carried out using nonparametric tests: the Kruskal–
Wallis test followed by Dunn’s multiple-comparison test
for in vitro experiments and the Mann–Whitney test for
in vivo experiments (one-tailed P-value for in vivo
experiments).
Results
In an in vitromodel of ischemia consisting of OGD in
rat organotypic hippocampal slices, the administra-
tion of 4mmol/L L-lactate directly after OGD
significantly decreased neuronal cell death in the
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CA1 region of the hippocampus at 48h, from
31±12% to 7±5%, whereas lower (1mmol/L) or
higher (20mmol/L) doses of L-lactate did not have a
significant protective effect (Figure 1). The higher
dose of 20mmol/L L-lactate was in fact toxic without
OGD, inducing 15% to 20% cell death at 48 h (data
not shown). This toxicity was not due to medium
acidification, as we could not detect any change in
the pH of the medium after L-lactate addition at 4
or 20mmol/L (data not shown), but could be due to
increased osmolarity.
On the basis of this apparent neuroprotective effect
of lactate in vitro, we studied the potential beneficial
effect of lactate administration in vivo after 30mins
of MCAO under xylazine–ketamine anesthesia. A
volume of 2mL of 100mmol/L L-lactate or 1PBS
was randomly administered intracerebroventricu-
larly, directly after reperfusion, and L-lactate was
found to significantly (P=0.05) reduce lesion size
from 104±42mm3 (control group) to 63±48mm3
(lactate group), 48 h after ischemia. The same result
was observed when calculating indirect lesion size
to avoid bias due to edema (Swanson et al, 1990)
(Figure 2A). When lesions were measured separately
in each brain structure, it appeared that lactate did
not significantly protect the cortex or hippo-
campus, but interestingly induced a very significant
decrease in lesion size in the striatum from 23±8 to
11±7mm3 (P=0.007) (Figure 2B).
To determine whether the neuroprotective effect of
lactate in vivo is present under different anesthetic
conditions and longer ischemia duration, we carried
out a second set of experiments with 60mins MCAO
in mice under isoflurane anesthesia. This set of
experiments was blinded and was carried out
randomly. In addition, behavior was assessed. In
these conditions, 48 h after ischemia, lesions of
control mice were similar to those produced by the
aforementioned 30mins MCAO under xylazine–
ketamine anesthesia. Lactate administration had
a small, nonsignificant (P=0.06), protective effect
(from 112±30mm3 for control mice to 94±18mm3
for lactate-injected mice) (Figure 3A). Once again,
when locating the lesion among the cortex, striatum,
and hippocampus, no protection after lactate treat-
ment was observed in the cortex and hippocampus.
However, lactate induced a significant reduction
in lesion size in the striatum (from 19±3mm3 for
control mice to 14±4mm3 for lactate-injected mice,
P=0.036) (Figure 3B). Lactate administration signifi-
cantly improved the neuroscore at 48h from 5.3±1.7
for control mice to 3.6±1.3 for lactate-treated mice
(P=0.046) (Figure 3C).
In an attempt to delineate the therapeutic window
of lactate administration, 11 mice were injected
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Figure 1 Administration of 4mmol/L L-lactate after OGD is
neuroprotective. Rat organotypic hippocampal slices were
subjected to 30mins of OGD. Various doses of L-lactate were
administered to the medium directly after OGD. Cell death was
assessed by propidium iodide staining at 48h after OGD.
***P<0.001 for the Kruskal–Wallis test, followed by Dunn’s
multiple-comparison test. Open circles represent one well of four
organotypic hippocampal slices.
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Figure 2 Injection of 2 mL of 100mmol/L L-lactate intracereb-
roventricularly directly after reperfusion is neuroprotective after
30mins of MCAO under xylazine–ketamine anesthesia. (A) Total
direct and indirect lesion sizes were measured at 48h after
ischemia. Black bars represent control mice, and white bars
represent mice injected with lactate. (B) Striatal lesion.
*P<0.05 and **P<0.01 for the Mann–Whitney test,
one-tailed P-value. Circles represent individual animals.
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intracerebroventricularly with either PBS or
100mmol/L lactate (2 mL of each) 60mins after the
end of 60mins MCAO under isoflurane anesthesia
and were killed at 48 h. The secondary anesthesia
required for the intracerebroventricular injection
with xylazine–ketamine by itself had a protective
effect, resulting in lesions of 78±22mm3 compared
with those of 112±30mm3 as described in Figure
3A. Lactate injection at this later time point was not
significantly neuroprotective, neither on the total
lesion (Figure 4A) nor in the striatum (Figure 4B).
However, it had a striking effect on the behavior of
these mice, decreasing their neuroscores very sig-
nificantly (P=0.009) at 48 h, from 4.9±2.2 in control
mice to 1.4±0.9 in lactate-injected mice (Figure 4C).
Moreover, Table 1 shows for this set of mice that
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Figure 3 Injection of 2 mL of 100mmol/L L-lactate intracereb-
roventricularly directly after reperfusion protects the striatum
after 60mins of MCAO under isoflurane anesthesia. (A) Total
direct and indirect lesion sizes were measured at 48h after
ischemia. Black bars represent control mice and white bars
represent mice injected with lactate. (B) Striatal lesion.
(C) Neurologic deficit scores from 0 (no deficit) to 9.
*P<0.05 for the Mann–Whitney test, one-tailed P-value.
Circles represent individual animals.
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Figure 4 Injection of 2 mL of 100mmol/L L-lactate intracereb-
roventricularly, 120mins after the beginning of 60mins of
MCAO under isoflurane anesthesia, improves neurologic out-
come, but does not significantly decrease lesion size. (A) Total
direct and indirect lesion sizes were measured at 48h after
ischemia. Black bars represent control mice and white bars
represent mice injected with lactate. (B) Striatal lesion.
(C) Neurologic deficit scores from 0 (no deficit) to 9.
**P<0.01 for the Mann–Whitney test, one-tailed P-value.
Circles represent individual animals.
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control mice lost significantly more weight (P=0.04)
than did lactate-injected mice, reflecting a better
neurologic outcome in treated animals.
With other neuroprotective agents tested after
ischemia, in the majority of cases, protection appears
in the cortex, which is less severely injured by
MCAO. In an attempt to understand why lactate
protected mainly the striatum in this study, we
measured lactate concentrations in the striatum and
cortex of healthy mice by MR spectroscopy before
and after injecting 2 mL of 100mmol/L L-lactate
intracerebroventricularly. At the same time, this
procedure allowed us to check the localization of
lactate injection by MR imaging (Figure 5A). Before
Table 1 Effect of anesthesia and lactate on physiological parameters
Xylasine–ketamine Isoflurane Isoflurane (120mins)
Control Lactate Control Lactate Control Lactate
CBF during ischemia (% of baseline) 19±6 17±8 20±6 16±3 18±4.4 15±5
CBF after ischemia (% of baseline) 80±14 76±17 74±18 72±14 72±19 83±23
Temperature during ischemia (1C) 37.0±0.5 37.1±0.3 36.8±0.2 36.9±0.3 36.9±0.4 36.9±0.1
Temperature at killing (1C) 35.5±0.9 36.1±1.2 35.9±0.9 35.7±0.7 35.6±0.7 36.3±0.4
Body weight loss (g) 7±1.6 5.2±2.1 6.4±1.6 6.4±1.3 7±1.4 5±1.6*
CBF, cerebral blood flow.
*P=0.04
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Figure 5 Intracerebroventricular injection of 2 mL of 100mmol/L L-lactate in healthy mice significantly increased lactate
concentration in the striatum and in the cortex. (A) MRI of one mouse injected with lactate, showing the site of injection (arrowhead)
and the VOIs used for MRS measurements in the striatum (6.4 mL, yellow square) and in the cortex (2.5 mL, red square).
(B) Evolution of lactate concentrations measured in the striatum and in the cortex of lactate-injected mice by MRS. (C) Typical
localized 1H-spectra from mouse striatum and cortex after treatments. All spectra were acquiredB30mins after PBS injection (the
left column) and lactate injection (the right column) from one of each mouse striatum (the top row) and cortex (the bottom row).
Spectra were processed with Gaussian apodization (gf=0.08 secs) and scaled relatively to the heights of both PCr+Cr and Mac,
which were indicated in the spectrum of PBS-treated striatum along with other major metabolites, such as NAA, Tau, and myo-Ins.
Dotted lines were drawn on the basis of the heights of lactate peaks from the spectra of PBS-treated striatum and cortex.
Abbreviations: Cr, creatine; Lac, lactate; Mac, macromolecule; myo-Ins, myo-inositol; NAA, N-acetyl-aspartate; PCr, phosphocrea-
tine; Tau, taurine. *P<0.05 for the Kruskal–Wallis test, followed by Dunn’s multiple-comparison test.
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injection, lactate concentrations were consistently
higher in the striatum than in the cortex. After lactate
injection, lactate increased rapidly in the striatum
(from 5±0.7 to 7.7±1.1mmol/L) and cortex (from
2.2±0.4 to 3.5±0.4mmol/L) and remained high for
1 h after injection (Figure 5B), whereas no significant
change was observed after PBS injection (Figure 5C).
At 90mins after injection, lactate concentrations
returned to control values (Figure 5B). Therefore,
the intracerebroventricular injection of lactate
rapidly increased lactate concentrations both in
the striatum and in the cortex, but concentrations
in the cortex increased to a lesser extent.
Discussion
The results presented in this study show, using three
different models, that lactate administered at early
time points after ischemia can indeed protect against
cell death, decrease lesion size, and improve
neurologic outcome.
In vitro, the addition of 4mmol/L Na L-lactate to
the medium directly after OGD was clearly neuro-
protective. Owing to the fact that lactate concentra-
tions in a rat brain at the p10 stage of development
are approximately 1 to 1.5mmol/L (Tkac et al, 2003),
the addition of 1mmol/L L-lactate will mean that the
medium will have the same lactate concentration
as that of the hippocampal tissue, which may not be
sufficient enough to achieve neuroprotection. In
contrast, the higher lactate concentration (20mmol/L)
induced cell death in these cultures, even without
any OGD (data not shown), and thus could not
protect against OGD-induced cell death. Lactate
increase after ischemia is believed to be toxic by
causing acidosis. Indeed, acid-sensing ion channels
have been shown to be activated after ischemia
(Xiong et al, 2004) and their inhibition to be
neuroprotective (Pignataro et al, 2007). However, in
our experiments, we could not detect any significant
change in the pH of the medium after the addition of
L-lactate (1, 4, or 20mmol/L). In addition, the pH
always remained higher than 7.2, whereas acid-
sensing ion channels could only be activated at a
pH lower than 7. Moreover, it has been shown in
astrocyte cultures that Na-lactate, even at high
concentrations (35mmol/L), does not cause acidosis,
in contrast to lactic acid (Morishima et al, 2008).
However, we only measured pH in the medium and
could not exclude an intracellular acidification due
to L-lactate administration, which could have toxic
effects. Another study showed that 20mmol/L Na
L-lactate can induce swelling and nucleotide release
as a consequence of intracellular acidification
(Phillis and O’Regan, 2002), a fact that could explain
the toxicity observed in our experiments.
The conditions we used for MCAO in this study
induced very large lesions covering more than half of
the left hemisphere. In these conditions, the penum-
bra is reduced to a small rim around the ischemic
core and neuroprotection might be difficult to obtain
(as reviewed in Hossmann (2008)). The 40% reduc-
tion in lesion size that was observed under xylazine–
ketamine anesthesia is thus very impressive. With
isoflurane anesthesia (Sakai et al, 2007), a longer
duration of ischemia resulted in a similar lesion size,
which was ascribed to isoflurane protection (Sakai
et al, 2007). Under these conditions, in which
isoflurane protects, an additional beneficial effect
of lactate may be more difficult to show. Moreover,
isoflurane neuroprotection might already involve
lactate, because lactate has been shown to increase
in the medium of cells treated with isoflurane
(Brabec et al, 1984). Although the total lesion
size was not affected by lactate treatment under
isoflurane anesthesia, lactate significantly reduced
the striatal lesion with both types of anesthesia,
when administered at reperfusion. Striatal protection
was unexpected, as this structure is the first to be
damaged after a milder ischemia (Lei et al, 2009),
probably because it is less well irrigated by collateral
circulation. Therefore, we speculated whether the
intracerebroventricularly injected lactate reached the
striatum and cortex evenly. The results presented
in Figure 5 show that lactate was distributed in both
structures. However, basal concentrations were
significantly different between these two regions
as already observed by other groups (Tkac et al,
2004). Thus, the 1mmol/L increase observed in the
cortex might not be sufficient enough for protection,
consistent with in vitro experiments (Figure 1),
whereas the striatal increase between 2 and
4mmol/L might be more efficient. However, at 48 h,
the cortical lesion may still be evolving in our model
and thus a protection of the cortex by lactate may
become apparent only at later time points.
The protective effect of lactate treatment observed
in this study might be surprising, because endo-
genous lactate is known to increase dramatically
after ischemia (Malisza et al, 1998). Without lactate
injection, lactate has been shown to increase during
ischemia because of anaerobic glycolysis, normal-
izing within 15mins after reperfusion in the rat after
2 h MCAO (Higuchi et al, 1996) and strongly
increasing from 1h after reperfusion, from 12mins
global ischemia or 2 to 3 h MCAO in the rat
(Michaelis et al, 1999; Thoren et al, 2006). One
possible explanation for a lactate decrease at reperfu-
sion could be the preferential consumption of lactate
when adenosine triphosphate stores deplete. Indeed,
adenosine triphosphate is required for the phosphor-
ylation of glucose to produce glucose-6-phosphate
for glycolysis, whereas lactate can directly be
metabolized without an investment of adenosine
triphosphate (Schurr, 2006). Moreover, Schurr et al
(1997a, b, c) showed that, at least in vitro, lactate
produced by astrocytes can be used after hypoxia
and is even preferred to glucose, which our results
support. At later time points, increased lactate is
probably not because of a lack of blood supply and
anaerobic metabolism, as glucose levels in the
Neuroprotective role of lactate
C Berthet et al
1786
Journal of Cerebral Blood Flow & Metabolism (2009) 29, 1780–1789
ischemic core are already normalized 2h 30mins
after reperfusion (Lei et al, 2009), but might be due
to the metabolism of macrophages infiltrating into
the brain after ischemia (Petroff et al, 1992) or may
possibly reflect the fact that lactate transporters
(Kuhr et al, 1988; Walz and Mukerji, 1988) have
changed, so that the lactate clearance rate is altered
relative to the synthesis rate. On the basis of our
in vitro experiments, lactate seems to be neuropro-
tective at low doses and toxic at higher concentra-
tions. Thus, lactate increases induced by ischemia
might protect in the beginning and become toxic later
when it reaches higher concentrations. After 1 h of
reperfusion in the rat, lactate increases between
30 (Michaelis et al, 1999) and 300% (Thoren et al,
2006), depending on the model. Owing to technical
limitations, we did not measure lactate concentration
1h after reperfusion in our model. However, under
isoflurane anesthesia, a 30-min MCAO induced a
3mmol/L increase in lactate 2 h after reperfusion
compared with that in control animals (Lei et al,
2009), which is similar to the increase observed after
lactate injection (Figure 5). As lactate has been
shown to increase rapidly during the first 20mins
of ischemia, but to be stable thereafter (Hopwood
et al, 2005), the concentration of lactate at reperfu-
sion should be similar in our 30- and 60-min models
of MCAO. It might thus be possible that endogenous
lactate is already increased at 1h of reperfusion and
available in a sufficient amount to fulfill metabolic
requirements; therefore, lactate administration is not
beneficial compared with endogenous lactate. This
might explain why it influenced neither the total
nor the striatal lesion. Conversely, Higuchi et al
(1996) showed a decrease in lactate concentration
from the end of ischemia until 15mins of reperfu-
sion, but no change thereafter until 1 h after
reperfusion from 1h of ischemia in the rat. If the
lactate evolution in our model is similar, endogenous
lactate concentration should be higher at reperfu-
sion than 1h later; thus, the difference in protection
observed between the two time points of lactate
injection could not be explained. However, these are
only speculations and we will need to measure
the exact early evolution of lactate after ischemia
in our model and control plasma glucose to
better understand a possible relationship between
endogenous and injected lactate. Conversely, the
expression of MCTs (monocarboxylate transporters),
which are necessary for lactate internalization, has
been shown to be influenced by ischemia, decreasing
in some cells and increasing in others (reviewed in
Pierre and Pellerin (2005)). However, MCT 1 and 2
seem to be stably expressed after ischemia, at least
for 4 h (Zovein et al, 2004), as well as lactate
dehydrogenase, which might even increase (Calvert
et al, 2006). Thus, neither a reduction in MCTs nor a
reduction in lactate dehydrogenase should be the
reason for the lack of effect of lactate injected 60mins
after reperfusion in our experiments. However, the
short therapeutic window we observe with lactate
in this severe ischemic model is not surprising,
because the length of the therapeutic window of
other neuroprotective agents has been shown to
decrease with severity of ischemia (e.g., D-JNKI1;
Hirt et al (2004)).
In view of a potential clinical application, the
substantial improvement in neurologic outcomes is
extremely interesting. In our study, we observed a
significant improvement in the neuroscore assessed
at 48 h after ischemia when lactate was administered
at reperfusion, and even more, when it was adminis-
tered 1h after reperfusion. In addition, with this later
administration, mice lost significantly less weight
than did control animals, which is another indica-
tion of improvement of the animal’s health status
(Modo et al, 2000). However, there is a discrepancy
between the lesion volume and the neurologic
outcome of these mice (injected at 120mins after
the onset of ischemia). This could be explained if
lactate had different effects depending on the
moment of administration. When injected at reperfu-
sion, it might be metabolized and might promote the
survival of neurons, as reflected in the observed
decrease in lesion size. There is no effect on lesion
volume 1h after reperfusion, although lactate supply
could possibly improve the performances of suffer-
ing, but surviving, neurons. However, its beneficial
effect on neurologic outcome suggests that it could
influence other mechanisms that still need to be
discovered; this hypothetical action is beyond the
scope of this study.
Knowing that lactate can be used as an energy
substrate by neurons (Schurr et al, 1988), and that it
can be used even when adenosine triphosphate
stores are depleted, we believe that at least a part of
the beneficial effect of lactate treatment might be due
to its metabolic utilization. However, we have no
experimental data to support this hypothesis and we
cannot exclude the presence of another mechanism.
For example, lactate might influence osmolarity,
which could have beneficial effects on edema when
moderate (with 4mmol/L lactate), but could become
toxic with higher concentrations of lactate. Another
explanation for the in vivo results could be the
lactate effects on CBF. Shackford et al (1994) showed
a decrease in cerebral vascular resistance leading
to increased CBF after lactate infusion. Moreover,
peri-infarct depolarizations after ischemia, which are
increased with hypoglycemia, have been shown to
lead to vasoconstriction (Strong et al, 2007). There-
fore, addition of lactate may not have a direct
survival effect, but may give energy to reduce the
number of peri-infarct depolarizations and reduce
the associated vasoconstriction. Our in vitro data,
however, show that the neuroprotection observed
after lactate treatment is not only due to CBF changes.
In any case, understanding the mechanism underlying
the protective effect of lactate injection is of great
interest and will be a subject for further studies.
In conclusion, lactate administration directly to
the brain after reperfusion can effectively protect
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against ischemia-induced cell death and disability.
In view of a potential clinical application, the next
step will be to test whether lactate can have the same
beneficial effects when injected intravenously,
which can be expected knowing that blood lactate
is an important energy source for the human brain
(van Hall et al, 2009).
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